» Articles » PMID: 35327418

Bezafibrate Reduces Elevated Hepatic Fumarate in Insulin-Deficient Mice

Abstract

Glucotoxic metabolites and pathways play a crucial role in diabetic complications, and new treatment options which improve glucotoxicity are highly warranted. In this study, we analyzed bezafibrate (BEZ) treated, streptozotocin (STZ) injected mice, which showed an improved glucose metabolism compared to untreated STZ animals. In order to identify key molecules and pathways which participate in the beneficial effects of BEZ, we studied plasma, skeletal muscle, white adipose tissue (WAT) and liver samples using non-targeted metabolomics (NMR spectroscopy), targeted metabolomics (mass spectrometry), microarrays and mitochondrial enzyme activity measurements, with a particular focus on the liver. The analysis of muscle and WAT demonstrated that STZ treatment elevated inflammatory pathways and reduced insulin signaling and lipid pathways, whereas BEZ decreased inflammatory pathways and increased insulin signaling and lipid pathways, which can partly explain the beneficial effects of BEZ on glucose metabolism. Furthermore, lysophosphatidylcholine levels were lower in the liver and skeletal muscle of STZ mice, which were reverted in BEZ-treated animals. BEZ also improved circulating and hepatic glucose levels as well as lipid profiles. In the liver, BEZ treatment reduced elevated fumarate levels in STZ mice, which was probably due to a decreased expression of urea cycle genes. Since fumarate has been shown to participate in glucotoxic pathways, our data suggests that BEZ treatment attenuates the urea cycle in the liver, decreases fumarate levels and, in turn, ameliorates glucotoxicity and reduces insulin resistance in STZ mice.

Citing Articles

Recent Advances in the Treatment Strategies of Friedreich's Ataxia: A Review of Potential Drug Candidates and their Underlying Mechanisms.

Saini A, Anil N, Vijay A, Mangla B, Javed S, Kumar P Curr Pharm Des. 2024; 30(19):1472-1489.

PMID: 38638052 DOI: 10.2174/0113816128288707240404051856.


Bezafibrate alleviates diabetes-induced spermatogenesis dysfunction by inhibiting inflammation and oxidative stress.

Mu Y, Luo L, Wu S, Gao Y, Qin X, Zhao J Heliyon. 2024; 10(6):e28284.

PMID: 38533024 PMC: 10963653. DOI: 10.1016/j.heliyon.2024.e28284.


Parental sex-dependent effects of either maternal or paternal eNOS deficiency on the offspring's phenotype without transmission of the parental eNOS deficiency to the offspring.

Zhang X, Reichetzeder C, Liu Y, Hocher J, Hasan A, Lin G Front Physiol. 2024; 14:1306178.

PMID: 38169827 PMC: 10758467. DOI: 10.3389/fphys.2023.1306178.

References
1.
Sampath H, Ntambi J . Stearoyl-coenzyme A desaturase 1, sterol regulatory element binding protein-1c and peroxisome proliferator-activated receptor-alpha: independent and interactive roles in the regulation of lipid metabolism. Curr Opin Clin Nutr Metab Care. 2006; 9(2):84-8. DOI: 10.1097/01.mco.0000214564.59815.af. View

2.
Krako Jakovljevic N, Pavlovic K, Jotic A, Lalic K, Stoiljkovic M, Lukic L . Targeting Mitochondria in Diabetes. Int J Mol Sci. 2021; 22(12). PMC: 8233932. DOI: 10.3390/ijms22126642. View

3.
Pickens C, Vazquez A, Jones A, Fenton J . Obesity, adipokines, and C-peptide are associated with distinct plasma phospholipid profiles in adult males, an untargeted lipidomic approach. Sci Rep. 2017; 7(1):6335. PMC: 5524758. DOI: 10.1038/s41598-017-05785-0. View

4.
Flory J, Ellenberg S, Szapary P, Strom B, Hennessy S . Antidiabetic action of bezafibrate in a large observational database. Diabetes Care. 2009; 32(4):547-51. PMC: 2660490. DOI: 10.2337/dc08-1809. View

5.
Chantrel-Groussard K, Geromel V, Puccio H, Koenig M, Munnich A, Rotig A . Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum Mol Genet. 2001; 10(19):2061-7. DOI: 10.1093/hmg/10.19.2061. View